UB CBE alumnus Mingfu Chen, MS 2015 from the Blaine Pfeifer research group, is responsible for the execution of advancing diagnostic biosensor research at Boston University (BU), where he now works as a biomedical engineer.
The National Institutes of Health (NIH) has launched the Rapid Acceleration of Diagnostics (RADx) Initiative. In response to NIH’s RADx Initiative, Chen is working with other researchers to develop rapid, easy-to-use testing technologies for SARS-CoV-2 at SiPhox Inc. CRISPR-based RNA detection amplified by plasmon resonance and silicon photonic resonator readout, delivers speed, sensitivity and specificity. If successful, such testing which will facilitate the speedy identification and quarantine of infected individuals and their contacts, and will likely be a critical component of making it possible for Americans to get safely back into public spaces, including returning to work and school. The final product will be a Point-of-Care diagnostic testing device. Chen’s responsibility as a biomedical engineer is development and understanding of comprehensive technology standards and practices, leading the strategy for technology platforms, and coordinating and support of partnerships.